GRAIL Study To Evaluate Multi-Cancer Early Detection Test for Medicare Population
The study will assess the clinical impact of the Galleri test in addition to recommended cancer screenings in the Medicare population.
The study will assess the clinical impact of the Galleri test in addition to recommended cancer screenings in the Medicare population.
PreciseBreast, an AI-powered digital morphology tool, has a fast turnaround time and is cost-effective compared to gene expression tests.
Roche announced the U.S. FDA approved the cobas HPV test for use on its next-generation cobas 5800 molecular instrument.
Roche is collaborating with Ibex and AWS to enable pathology labs to access AI-powered decision support tools to support cancer diagnosis.
Read MoreQIAGEN and Myriad Genetics announced a new master collaboration agreement to develop companion diagnostic tests in the field of cancer.
Read MoreAlercell’s leukemia test will use terminal erythroid differentiation for prognostic classification in patients with myeloid malignancies.
Read MoreThe liquid biopsy platform provides resolution into the activation status of individual disease-defining genes and pathways genome-wide.
Read MoreResearchers have developed an artificial intelligence (AI) tool for automatic colorectal cancer tissue analysis.
Read MoreResearchers detected cancer earlier in individuals with Li-Fraumeni syndrome, an inherited condition with a high risk of developing cancer.
Read MoreLiquid biopsy may be used to improve the response to standard chemotherapy regimens in patients with stage III or stage II colon cancer.
Read MoreA research team investigated the extent to which diagnosis and therapy of pigmented skin lesions benefit from AI in a clinical scenario.
Read MoreVolitionRx detailed a new liquid biopsy cancer-detection method at the annual congress of the European Society for Medical Oncology.
Read MoreNeXT Personal ctDNA assay shown to be more sensitive and predictive of clinical outcomes in early-stage lung cancer patients
Read MoreCollaboration leverages two CDx assays from Thermo Fisher to support greater access to genomic testing for cancer patients.
Read MoreThe University of Illinois Chicago will participate in a study of a test that screens for a shared cancer signal in patient blood samples.
Read MoreArteraAI will present data demonstrating the successful validation of its prognostic model in advanced prostate cancer.
Read MoreInvitae announced the results of its study on universal hereditary cancer genetic testing in breast cancer patients in a rural population.
Read MoreBiocartis and APIS Assay Technologies are expanding their collaboration to include the commercialization of the APIS ESR1 Mutations Kit.
Read More